HIV associated nephropathy future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{HIV associated nephropathy}} | {{HIV associated nephropathy}} | ||
{{CMG}} {{AE}} {{SHA}} | |||
== Overview == | == Overview == | ||
| Line 7: | Line 8: | ||
== Future or Investigational Therapies == | == Future or Investigational Therapies == | ||
* more research is needed to determine novel therapies such as molecular targeting to prevent or delay progression to ESRD. | * more research is needed to determine novel therapies such as molecular targeting to prevent or delay progression to ESRD. <ref name="pmid29224373">{{cite journal| author=Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG| title=Pharmacotherapy and treatment options for HIV-associated nephropathy. | journal=Expert Opin Pharmacother | year= 2018 | volume= 19 | issue= 1 | pages= 39-48 | pmid=29224373 | doi=10.1080/14656566.2017.1416099 | pmc=6381591 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29224373 }} </ref> | ||
* The initiation of HIV-positive donor to HIV-positive recipient kidney transplantation, in South Africa and now available in the United States, offers great promise to patients who previously may not have survived to transplantation, though long-term outcomes remain unclear as well as the lack of data on estimated risk of recurrent disease. | * The initiation of HIV-positive donor to HIV-positive recipient kidney transplantation, in South Africa and now available in the United States, offers great promise to patients who previously may not have survived to transplantation, though long-term outcomes remain unclear as well as the lack of data on estimated risk of recurrent disease. | ||
*Recently, there have been reports from USA and South Africa that have shown successful kidney transplantation from HIV-positive donors to HIV-positive recipients.<ref name="pmid25671253">{{cite journal| author=Muller E, Barday Z, Mendelson M, Kahn D| title=HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. | journal=N Engl J Med | year= 2015 | volume= 372 | issue= 7 | pages= 613-20 | pmid=25671253 | doi=10.1056/NEJMoa1408896 | pmc=5090019 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25671253 }} </ref><ref name="pmid27043422">{{cite journal| author=Durand CM, Segev D, Sugarman J| title=Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors. | journal=Ann Intern Med | year= 2016 | volume= 165 | issue= 2 | pages= 138-42 | pmid=27043422 | doi=10.7326/M16-0560 | pmc=4949150 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27043422 }} </ref> | |||
* HIV superinfection and resistance to cART are among the most concerning risks in kidney transplantation in HIV-positive kidneys to HIV-positive recipients.<ref name="pmid29330339">{{cite journal| author=Muller E, Barday Z| title=HIV-Positive Kidney Donor Selection for HIV-Positive Transplant Recipients. | journal=J Am Soc Nephrol | year= 2018 | volume= 29 | issue= 4 | pages= 1090-1095 | pmid=29330339 | doi=10.1681/ASN.2017080853 | pmc=5875954 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29330339 }} </ref> | |||
==References== | ==References== | ||
Revision as of 06:31, 26 June 2020
|
HIV associated nephropathy Microchapters |
|
Differentiating HIV associated nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV associated nephropathy future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of HIV associated nephropathy future or investigational therapies |
|
FDA on HIV associated nephropathy future or investigational therapies |
|
CDC on HIV associated nephropathy future or investigational therapies |
|
HIV associated nephropathy future or investigational therapies in the news |
|
Blogs on HIV associated nephropathy future or investigational therapies |
|
Risk calculators and risk factors for HIV associated nephropathy future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Future or Investigational Therapies
- more research is needed to determine novel therapies such as molecular targeting to prevent or delay progression to ESRD. [1]
- The initiation of HIV-positive donor to HIV-positive recipient kidney transplantation, in South Africa and now available in the United States, offers great promise to patients who previously may not have survived to transplantation, though long-term outcomes remain unclear as well as the lack of data on estimated risk of recurrent disease.
- Recently, there have been reports from USA and South Africa that have shown successful kidney transplantation from HIV-positive donors to HIV-positive recipients.[2][3]
- HIV superinfection and resistance to cART are among the most concerning risks in kidney transplantation in HIV-positive kidneys to HIV-positive recipients.[4]
References
- ↑ Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG (2018). "Pharmacotherapy and treatment options for HIV-associated nephropathy". Expert Opin Pharmacother. 19 (1): 39–48. doi:10.1080/14656566.2017.1416099. PMC 6381591. PMID 29224373.
- ↑ Muller E, Barday Z, Mendelson M, Kahn D (2015). "HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years". N Engl J Med. 372 (7): 613–20. doi:10.1056/NEJMoa1408896. PMC 5090019. PMID 25671253.
- ↑ Durand CM, Segev D, Sugarman J (2016). "Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors". Ann Intern Med. 165 (2): 138–42. doi:10.7326/M16-0560. PMC 4949150. PMID 27043422.
- ↑ Muller E, Barday Z (2018). "HIV-Positive Kidney Donor Selection for HIV-Positive Transplant Recipients". J Am Soc Nephrol. 29 (4): 1090–1095. doi:10.1681/ASN.2017080853. PMC 5875954. PMID 29330339.